Femasys Inc. (FEMY) 股票分析

公司概述

Femasys Inc. operates as a biomedical entity dedicated to developing therapeutic and diagnostic solutions aimed at addressing unmet healthcare needs for women, both within the United States and in international markets. The company functions within the healthcare sector, specifically specializing in the medical instruments and supplies industry, which implies a focus on high-barrier-to-entry products requiring regulatory approval and specialized manufacturing capabilities. According to the available data, Femasys Inc. holds a market capitalization of $23.87M, while its trailing twelve-month revenue stands at $2.29M, and the specific employee count is not disclosed in the provided facts. These valuation and revenue metrics indicate that the company operates on a micro-cap scale, suggesting it is in an early or growth stage where revenue generation is prioritized over profitability, and the lack of disclosed employee data prevents a direct assessment of labor intensity relative to its revenue base.

财务健康

The company reported revenue of $2.29M over the trailing twelve months, yet this revenue generated a net income loss of $-18,627,888 and an EBITDA of $-17,246,636, revealing a cost structure where operating expenses significantly outweigh gross profits. This substantial gap between the $2.29M revenue and the negative net income highlights a heavy burn rate typical of R-intensive biomedicals, where the cost of research, development, and clinical trials consumes the majority of cash flow before reaching the bottom line. Free cash flow stands at $-11,906,741, indicating that the company is currently converting its operations into cash outflows rather than generating liquidity, which limits financial flexibility and necessitates reliance on external capital or existing cash reserves. The gross margin is 62.0%, suggesting efficient production costs relative to sales, whereas the operating margin is -568.3% and profit margin is 0.0%, signaling that general and administrative expenses are disproportionately high, effectively erasing all gross profitability. The balance sheet shows a cash position of $9.27M against total debt of $4.70M, with a debt-to-equity ratio of 80.03, indicating a highly leveraged capital structure relative to equity but providing a net cash position that buffers against short-term solvency risks. The current ratio is 4.53, which indicates strong short-term liquidity and the ability to cover current liabilities more than four times over using available current assets. Return on equity is -455.8% and return on assets is -66.3%, metrics that reveal management has not yet achieved positive returns on shareholder capital or asset deployment, reflecting the inherent challenges of the development phase in the medical device industry.

估值评估

The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -1.11, implying that analysts or market models project continued negative earnings in the near term rather than immediate profitability. The price-to-book ratio is 4.12, which indicates that the market values the company at a significant premium over its net asset book value, potentially reflecting high growth expectations or intangible assets like intellectual property that are not fully captured on the balance sheet. The price-to-sales ratio is 10.41 and the EV/EBITDA is -1.12, suggesting that valuation is being driven primarily by revenue multiple expansion rather than earnings power, as the negative EV/EBITDA reinforces the expectation of future losses. The stock's 52-week high is $1.29 and the 52-week low is $0.31, meaning the current trading price sits within a wide historical range that captures substantial volatility and potential for price discovery as the company seeks a valuation commensurate with its growth trajectory. The beta is -2.28, a unique metric indicating that the stock price moves inversely to the broader market with high intensity, presenting a distinct risk profile where market downturns could theoretically correlate with unexpected upside or vice versa, though such negative beta behavior is rare and suggests specific idiosyncratic factors driving price action.

Growth & Income

Revenue growth year-over-year is 39.9%, while earnings growth is N/A due to the company's current unprofitability, implying that top-line expansion is the primary driver of value creation rather than margin expansion at this stage. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which explains that the firm reinvests all available cash flow back into product development, clinical trials, and market expansion rather than distributing income to shareholders. The lack of a dividend policy combined with negative earnings growth underscores the company's strategy of prioritizing long-term market penetration and product pipeline development over short-term income distribution for investors seeking yield. Overall, the company presents a pure growth profile characterized by accelerating revenue but persistent losses, requiring continuous capital infusion to sustain operations and achieve future profitability milestones.